Sunwels (9229) Q1 2026 earnings summary

Executive summary

• Opened 3 new PD House facilities in Q1 FY March 2026, bringing the total to 46 nationwide, with a focus on specialized care for Parkinson's disease.

• Net sales rose 5.9% year-over-year to ¥6,605 million for the three months ended June 30, 2025, but profitability declined due to initial costs from new facility openings and operational restructuring following compliance issues.

• Achieved 86% occupancy at existing facilities, but new facilities lagged at 14%.

• Continued expansion and human resource development, including compliance and ethics training.

Financial highlights

• Q1 FY March 2026 sales were ¥6,605 million, up 5.9% year-over-year.

• EBITDA for Q1 was ¥(95) million, down from ¥858 million YoY due to increased personnel and facility costs.

• Operating loss was ¥507 million, ordinary loss ¥687 million, and net loss ¥725 million, compared to profits in the prior year.

• Results were largely in line with forecasts, with a 95.8% achievement rate for sales.

Outlook and guidance

• Full-year sales forecast at ¥31,106 million, with continued facility openings planned and 13 new facilities scheduled for FY2026.

• Profitability expected to recover as new facilities ramp up occupancy, with measures underway to optimize personnel allocation.